Olaparib and Doxorubicin Co-Loaded Polypeptide Nanogel for Enhanced Breast Cancer Therapy

Overview

Journal Front Bioeng Biotechnol

Date 2022 May 19

PMID 35586554

Authors

Yanhong Liu

Meiyan Wang

Wanru Liu

Jili Jing

Hongshuang Ma

Affiliations

Soon will be listed here.

Abstract

Although great progress has been made in improving the efficacy of cancer treatment through combination treatment using drug agents, there are still challenges in improving the efficiency of drug delivery. In this study, olaparib and doxorubicin were co-loaded on disulfide bond cross-linked polypeptide nanogels for the treatment of breast cancer in mouse models. Under stimulation of a high glutathione environment in cancer cells, the drug is quickly released from the nanogel to target cancer cells. In addition, compared with free drugs and single-drug-loaded nanogels, dual-drug- co-loaded nanogels exhibit the best anti-cancer effect and demonstrated excellent biological safety. Therefore, the co-delivery of olaparib and doxorubicin through polypeptide nanogels presents good prospects for application as anti-cancer treatment.

Citing Articles

Nanogels-Innovative Drug Carriers for Overcoming Biological Membranes.

Radeva L, Yoncheva K Gels. 2025; 11(2).

PMID: 39996667 PMC: 11854394. DOI: 10.3390/gels11020124.

Hyaluronic acid-coated polypeptide nanogel enhances specific distribution and therapy of tacrolimus in rheumatoid arthritis.

Li Y, Wang X, Gao Y, Zhang Z, Liu T, Zhang Z J Nanobiotechnology. 2024; 22(1):547.

PMID: 39238027 PMC: 11378632. DOI: 10.1186/s12951-024-02784-y.

Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery.

Wang Z, Li W, Jiang Y, Park J, Gonzalez K, Wu X Nat Commun. 2024; 15(1):2073.

PMID: 38453918 PMC: 10920917. DOI: 10.1038/s41467-024-46331-7.

Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7 breast cancer cells.

Abdel-Sattar O, Allam R, Al-Abd A, Avula B, Katragunta K, Khan I Sci Rep. 2023; 13(1):2683.

PMID: 36792619 PMC: 9932073. DOI: 10.1038/s41598-023-29566-0.

Recent advances in cancer therapy using PARP inhibitors.

Kaur S, Chellappan D, Aljabali A, Tambuwala M, Dua K, Kapoor D Med Oncol. 2022; 39(12):241.

PMID: 36180646 DOI: 10.1007/s12032-022-01840-7.

References

Bixel K, Hays J . Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med. 2015; 8:127-35. PMC: 4538690. DOI: 10.2147/PGPM.S62809. View

Sun H, Guo B, Cheng R, Meng F, Liu H, Zhong Z . Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin. Biomaterials. 2009; 30(31):6358-66. DOI: 10.1016/j.biomaterials.2009.07.051. View

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

Eetezadi S, Evans J, Shen Y, De Souza R, Piquette-Miller M, Allen C . Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Mol Pharm. 2017; 15(2):472-485. DOI: 10.1021/acs.molpharmaceut.7b00843. View

Zhu H, Ding W, Wu R, Weng Q, Lou J, Jin R . Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2009; 28(1):23-32. DOI: 10.3109/07357900903095664. View

Pathmanathan N, Balleine R . Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6):512-6. DOI: 10.1136/jclinpath-2012-201085. View

Kong F, Liang Z, Luan D, Liu X, Xu K, Tang B . A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging. Anal Chem. 2016; 88(12):6450-6. DOI: 10.1021/acs.analchem.6b01135. View

Robert M, Frenel J, Gourmelon C, Patsouris A, Augereau P, Campone M . Olaparib for the treatment of breast cancer. Expert Opin Investig Drugs. 2017; 26(6):751-759. DOI: 10.1080/13543784.2017.1318847. View

10.

Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris J, Veronese F . A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem. 1995; 6(1):62-9. DOI: 10.1021/bc00031a006. View

11.

Aebi S, Gelber S, Anderson S, Lang I, Robidoux A, Martin M . Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014; 15(2):156-63. PMC: 3982874. DOI: 10.1016/S1470-2045(13)70589-8. View

12.

Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M . H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer. Sci Rep. 2017; 7(1):7505. PMC: 5548799. DOI: 10.1038/s41598-017-07617-7. View

13.

Pulaski B, Ostrand-Rosenberg S . Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2008; Chapter 20:Unit 20.2. DOI: 10.1002/0471142735.im2002s39. View

14.

Da Rocha M, da Silva P, Radicchi M, Andrade B, de Oliveira J, Venus T . Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnology. 2020; 18(1):43. PMC: 7068958. DOI: 10.1186/s12951-020-00604-7. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Li Q, Lv S, Tang Z, Liu M, Zhang D, Yang Y . A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. Int J Pharm. 2014; 471(1-2):412-20. DOI: 10.1016/j.ijpharm.2014.05.065. View

17.

Porter A, Janicke R . Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6(2):99-104. DOI: 10.1038/sj.cdd.4400476. View

18.

Anders C, Winer E, Ford J, Dent R, Silver D, Sledge G . Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010; 16(19):4702-10. PMC: 2948607. DOI: 10.1158/1078-0432.CCR-10-0939. View

19.

Wang J, Xu W, Zhang N, Yang C, Xu H, Wang Z . X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy. J Control Release. 2021; 332:1-9. DOI: 10.1016/j.jconrel.2021.02.003. View

20.

Liu J, Ai X, Cabral H, Liu J, Huang Y, Mi P . Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. Biomaterials. 2021; 273:120847. DOI: 10.1016/j.biomaterials.2021.120847. View